BridgeBio Pharma, Inc. Contracts & Agreements

Amended and Restated Limited Liability Company Agreement of GondolaBio, LLC, dated as of August 16, 2024 (Filed With SEC on August 21, 2024)

Transaction Agreement, dated as of August 16, 2024, by and among BridgeBio Pharma, Inc., Viking Global Opportunities Illiquid Investments Sub-Master LP, Viking Global... (Filed With SEC on August 21, 2024)

2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (Filed With SEC on June 24, 2024)

Underwriting Agreement, dated as of March 5, 2024, by and among the Company, J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives... (Filed With SEC on March 6, 2024)

Amendment to Employment Agreement, between BridgeBio Services, Inc. and Brian Stephenson, dated February 21, 2024 (Filed With SEC on February 22, 2024)

Letter Agreement, Amendment #1 thereto, and Amendments to License Agreement between QED Therapeutics, Inc. and Novartis International Pharmaceutical Ltd., dated May 4, 2018,... (Filed With SEC on February 22, 2024)

Second Amendment, effective as of August 15, 2023, to the Exclusive (Equity) Agreement, by and between Eidos Therapeutics, Inc. and the Board of Trustees of the Leland Stanford... (Filed With SEC on November 2, 2023)

Registration Rights Agreement, dated September 25, 2023, by and among BridgeBio Pharma, Inc. and the purchasers party thereto (Filed With SEC on September 25, 2023)

Securities Purchase Agreement, dated September 25, 2023, by and among BridgeBio Pharma, Inc. and the purchasers party thereto (Filed With SEC on September 25, 2023)

Form of Non-Qualified Stock Option Agreement under 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan for Board of Directors (2023 Form) (Filed With SEC on August 3, 2023)

Form of Restricted Stock Unit Award Agreement under BridgeBio Pharma, Inc. Amended and Restated 2019 Inducement Equity Plan (2023 Form) (Filed With SEC on August 3, 2023)

Form of Restricted Stock Award Agreement under BridgeBio Pharma, Inc. Amended and Restated 2019 Inducement Equity Plan (2023 Form) (Filed With SEC on August 3, 2023)

Form of Non-Qualified Stock Option Agreement under BridgeBio Pharma, Inc. Amended and Restated 2019 Inducement Equity Plan (2023 Form) (Filed With SEC on August 3, 2023)

Form of Restricted Stock Unit Award Agreement under 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (2023 Form) (Filed With SEC on August 3, 2023)

Form of Restricted Stock Award Agreement under 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (2023 Form) (Filed With SEC on August 3, 2023)

Form of Non-Qualified Stock Option Agreement under 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (2023 Form) (Filed With SEC on August 3, 2023)

Underwriting Agreement, dated as of March 7, 2023, by and among the Company, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Morgan Stanley & Co. LLC, as representatives of the... (Filed With SEC on March 9, 2023)

Amended and Restated Director Compensation Policy (Filed With SEC on February 25, 2022)

Description of Securities (Filed With SEC on February 25, 2022)

Amended and Restated 2021 Stock Option and Incentive Plan and forms of award agreements thereunder (Filed With SEC on February 25, 2022)

Loan and Security Agreement, among U.S. Bank National Association in its capacity as Administrative Agent and Collateral Agent, the Lenders party thereto, the Registrant, and... (Filed With SEC on February 25, 2022)

Amended and Restated Employee Stock Purchase Plan (Filed With SEC on November 4, 2021)

Amended and Restated Employee Stock Purchase Plan (Filed With SEC on May 6, 2021)

Sixth Amendment to the Loan and Security Agreement, between BridgeBio Pharma LLC and Hercules Capital, Inc., dated as of April 13, 2021 (Filed With SEC on May 6, 2021)

Fifth Amendment to the Loan and Security Agreement, between BridgeBio Pharma LLC and Hercules Capital, Inc., dated as of January 25, 2021 (Filed With SEC on February 25, 2021)

Third Amendment to the Loan and Security Agreement, between BridgeBio Pharma LLC and Hercules Capital, Inc., dated as of March 2, 2020 (Filed With SEC on February 25, 2021)

Description of Securities (Filed With SEC on February 25, 2021)

Underwriting Agreement, dated as of February 11, 2021, by and among the Company, the Selling Stockholder and Goldman Sachs & Co. LLC, as the representative of the several... (Filed With SEC on February 17, 2021)

Form of Confirmation for Capped Call Transactions (Filed With SEC on January 29, 2021)

Indenture, dated as of January 28, 2021, by and between BridgeBio Pharma, Inc. and U.S. Bank National Association, as Trustee (Filed With SEC on January 29, 2021)

Purchase Agreement, dated January 25, 2021, by and among BridgeBio Pharma, Inc. and J.P. Morgan Securities LLC and Mizuho Securities USA LLC, as representatives of the several... (Filed With SEC on January 26, 2021)

Amended and Restated 2019 Employee Stock Purchase Plan, effective December 12, 2019 (Filed With SEC on November 5, 2020)

Agreement and Plan of Merger, dated as of October 5, 2020, by and among BridgeBio Pharma, Inc., Eidos Therapeutics, Inc., Globe Merger Sub I, Inc. and Globe Merger Sub II, Inc (Filed With SEC on October 6, 2020)

Indenture, dated as of March 9, 2020, by and between BridgeBio Pharma, Inc. and U.S. Bank National Association, as Trustee (Filed With SEC on March 10, 2020)

Form of Confirmation for Capped Call Transactions (Filed With SEC on March 10, 2020)

Purchase Agreement, dated March 4, 2020, by and among BridgeBio Pharma, Inc. and J.P. Morgan Securities LLC and BofA Securities, Inc., as representatives of the several Initial... (Filed With SEC on March 6, 2020)

Director Compensation Policy (Filed With SEC on March 3, 2020)

Collaboration Agreement, by and between BridgeBio Gene Therapy, LLC and Catalent Maryland, Inc., formerly Paragon Bioservices, Inc., dated December 31, 2019 (Filed With SEC on March 3, 2020)

Offer Letter, between BridgeBio Pharma, Inc. and James C. Momtazee, dated February 23, 2020 (Filed With SEC on March 3, 2020)

Consulting Agreement, between Jennifer E. Cook and the Registrant, effective as of October 14, 2019 (Filed With SEC on March 3, 2020)

Fourth Amendment to the Exclusive License Agreement, between The Regents of the University of California and TheRas, Inc., dated December 16, 2019 (Filed With SEC on March 3, 2020)

Description of Securities (Filed With SEC on March 3, 2020)

Loan and Security Agreement dated November 13, 2019 between Eidos Therapeutics, Inc., a partially owned subsidiary of Registrant, as borrower, Silicon Valley Bank and Hercules... (Filed With SEC on November 19, 2019)

Offer Letter, between BridgeBio Pharma, Inc. and Brian Stolz, dated September 19, 2019 (Filed With SEC on November 8, 2019)

Offer Letter, between and BridgeBio Services, Inc. and Yi Ching Yau, dated September 9, 2019 (Filed With SEC on November 8, 2019)

License Agreement, by and between the Registrant and Alexion Pharma International Operations Unlimited Company, dated September 9, 2019 (Filed With SEC on November 8, 2019)

Registration Rights Agreement (Filed With SEC on July 3, 2019)

Indemnification Agreement, between BridgeBio Pharma LLC and KKR Genetic Disorder, L.P., dated March 26, 2016 (Filed With SEC on June 24, 2019)

Form of Tax Sharing Agreement, between the Registrant and each of its subsidiaries (Filed With SEC on June 24, 2019)

Form of Indemnification Agreement, between the Registrant and each of its executive officers (Filed With SEC on June 24, 2019)

Form of Indemnification Agreement, between the Registrant and each of its directors (Filed With SEC on June 24, 2019)

Senior Executive Cash Incentive Bonus Plan (Filed With SEC on June 24, 2019)

2019 Employee Stock Purchase Plan (Filed With SEC on June 24, 2019)

2019 Stock Option and Incentive Plan and forms of award agreements thereunder (Filed With SEC on June 24, 2019)

Form of Registration Rights Agreement, among the Registrant and certain of its shareholders, to be in effect immediately prior to completion of this offering (Filed With SEC on June 24, 2019)

Specimen Common Stock Certificate (Filed With SEC on June 24, 2019)

Form of Underwriting Agreement (Filed With SEC on June 24, 2019)

Offer Letter, between Eidos Therapeutics, Inc. and Cameron Turtle, dated June 13, 2018 (Filed With SEC on June 11, 2019)

Offer Letter, between BridgeBio Services, Inc. and Cameron Turtle, dated December 13, 2016, as amended on May 5, 2017 (Filed With SEC on June 11, 2019)

Offer Letter, between BridgeBio Services, Inc. and Michael Henderson, dated March 22, 2016, as amended on May 5, 2017 (Filed With SEC on June 11, 2019)

Offer Letter, between BridgeBio Services, Inc. and Richard Scheller, dated April 5, 2019 (Filed With SEC on June 11, 2019)

Offer Letter, between BridgeBio Services, Inc. and Charles Homcy, dated February 20, 2019 (Filed With SEC on June 11, 2019)

Offer Letter, between Eidos Therapeutics, Inc. and Uma Sinha, dated June 1, 2016, as amended on May 24, 2018 (Filed With SEC on June 11, 2019)

Offer Letter, between BridgeBio Services, Inc. and Brian Stephenson, dated October 28, 2018 (Filed With SEC on June 11, 2019)

Offer Letter, between BridgeBio Services, Inc. and Neil Kumar, dated December 14, 2017 (Filed With SEC on June 11, 2019)

Fourth Amended and Restated Limited Liability Company Agreement, dated November 20, 2018, by and among BridgeBio Pharma LLC and its members (Filed With SEC on May 24, 2019)

Form of Registration Rights Agreement, among the Registrant and certain of its shareholders, to be in effect immediately prior to completion of this offering (Filed With SEC on May 24, 2019)

Loan and Security Agreement, between BridgeBio Pharma LLC and Hercules Capital, Inc., dated as of June 19, 2018 (Filed With SEC on May 24, 2019)

First Amendment to the Loan and Security Agreement, between BridgeBio Pharma LLC and Hercules Capital, Inc., dated as of December 28, 2018 (Filed With SEC on May 24, 2019)

Lease Agreement, between BridgeBio Pharma LLC and Michael J. Harbour, dated as of March 23, 2017 (Filed With SEC on May 24, 2019)

Exclusive (Equity) Agreement, by and between Eidos Therapeutics, Inc. and the Board of Trustees of the Leland Stanford Junior University, effective as of April 10, 2016, as... (Filed With SEC on May 24, 2019)

License Agreement, between QED Therapeutics, Inc. and Novartis International Pharmaceutical Ltd., dated as of January 29, 2018 (Filed With SEC on May 24, 2019)

Asset Purchase Agreement, among BridgeBio Pharma LLC, Origin Biosciences, Inc., and Alexion Pharma Holding Unlimited Company, dated as of June 7, 2018 (Filed With SEC on May 24, 2019)

Asset Purchase Agreement, among Phoenix Tissue Repair, Inc., Shire Human Genetic Therapies, Inc., and Lotus Tissue Repair, Inc., dated as of July 21, 2017 (Filed With SEC on May 24, 2019)

Exclusive License Agreement, between The Regents of the University of California and TheRas, Inc., dated September 28, 2016, as amended by First Amendment effective January 10,... (Filed With SEC on May 24, 2019)

Collaboration and License Agreement, between Navire Pharma, Inc. (formerly known as PTP Pharmaceuticals, Inc.) and the Board of Regents of the University of Texas System and The... (Filed With SEC on May 24, 2019)

Exclusive Patent License Agreement, between The Frederick National Laboratory for Cancer Research, operated by Leidos Biomedical Research, Inc., under sponsorship from the... (Filed With SEC on May 24, 2019)

Cell Line License Agreement, by and between Life Technologies Corporation and BridgeBio Services, Inc., effective as of November 15, 2018 (Filed With SEC on May 24, 2019)

Second Amendment to the Loan and Security Agreement, between BridgeBio Pharma LLC and Hercules Capital Inc., dated as of May 17, 2019 (Filed With SEC on May 24, 2019)

Option Agreement, among PellePharm, Inc., Leo Pharma A/S and Leo Spiny Merger Sub, Inc., dated as of November 19, 2018, as amended on March 13, 2019 (Filed With SEC on May 24, 2019)

Category

Industry

Companies

Contracts

BridgeBio Pharma, Inc. Contracts & Agreements